Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 2003

Primary Completion Date

April 30, 2006

Study Completion Date

December 31, 2007

Conditions
Leukemia
Interventions
BIOLOGICAL

sargramostim

Trial Locations (15)

27216

Alamance Cancer Center, Burlington

27858

Brody School of Medicine at East Carolina University, Greenville

28621

Hugh Chatham Memorial Hospital, Elkin

29303

CCOP - Upstate Carolina, Spartanburg

29615

Cancer Centers of the Carolinas - Eastside, Greenville

30165

Regional Radiation Oncology Center at Rome, Rome

33140

CCOP - Mount Sinai Medical Center, Miami Beach

40202

Kentuckiana Cancer Institute, PLLC, Louisville

43206

CCOP - Columbus, Columbus

62526

CCOP - Central Illinois, Decatur

70112

MBCCOP - LSU Health Sciences Center, New Orleans

85006-2726

CCOP - Western Regional, Arizona, Phoenix

94609-3305

CCOP - Bay Area Tumor Institute, Oakland

27534-9479

Southeastern Medical Oncology Center, Goldsboro

27157-1096

Comprehensive Cancer Center at Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT00072579 - Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment | Biotech Hunter | Biotech Hunter